Therefore, we hypothesized that CP treatment would reduce TGFβ1 expression and enhance T-cell-mediated tumoricidal effects, improving the effectiveness of immune checkpoint therapies in cancer treatment. This evidence concerns the gene TGFB1 and cancer.